Literature DB >> 26090374

Variant of multiple sclerosis with dementia and tumefactive demyelinating brain lesions.

Sherifa A Hamed1.   

Abstract

We describe an unusual clinical and diagnostic feature of a patient with multiple sclerosis (MS). A 25-year-old woman was admitted to the Neurology department (December 2009) with one month history of rapid cognitive deterioration. She had poor cognition, dysphasia, reduction in visual acuity and temporal pallor of the optic discs. She had prolonged latencies of P100 component of visual evoked potentials (VEPs). Magnetic resonance imaging (MRI)-brain showed multifocal large (≥ 3 cm) white-matter hypointense lesions in T1W and hyperintense in T2W and fluid-attenuated inversion recovery images and patchy enhancement. A diagnosis of tumefactive MS was given. She received two consecutive 5-d courses of 1 g daily intravenous methylprednisolone for 2 mo and oral prednisolone in dose of 80 mg twice/daily in between. At the 3(rd) month, Mini Mental State Examination and VEPs returned to normal but not the MRI. Patient continued oral steroids after hospital discharge (March 2010) for 9 mo with significant MRI improvement after which tapering of steroids started for a year. The patient refused immunomodulation therapy due to her low socioeconomic status. Neither clinical relapse nor new MRI lesions were observed throughout the next 4 years. In spite of the aggressive course of tumefactive MS variant, good prognosis may be seen in some patients.

Entities:  

Keywords:  Acute dementia; Tumefactive multiple sclerosis

Year:  2015        PMID: 26090374      PMCID: PMC4468900          DOI: 10.12998/wjcc.v3.i6.525

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  35 in total

1.  Marburg's disease: a diagnostic dilemma.

Authors:  Kirti Gupta; Rakesh Kumar Vasishta; Param Singh Kharbanda; Sameer Vyas; Sudesh Prabhakar
Journal:  Neurol Sci       Date:  2011-08-06       Impact factor: 3.307

2.  Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event.

Authors:  Pandurang R Wattamwar; Neeraj N Baheti; Chandrasekharan Kesavadas; Muralidharan Nair; Ashalatha Radhakrishnan
Journal:  J Neurol Sci       Date:  2010-08-01       Impact factor: 3.181

3.  Magnetic resonance imaging observations in primary central nervous system lymphoma.

Authors:  Justin T Jordan; Scott Plotkin; Jorg Dietrich
Journal:  JAMA Neurol       Date:  2014-07-01       Impact factor: 18.302

4.  Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

Authors:  Sean J Pittock; Brian G Weinshenker; Claudia F Lucchinetti; Dean M Wingerchuk; John R Corboy; Vanda A Lennon
Journal:  Arch Neurol       Date:  2006-07

5.  Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.

Authors:  Takao Kiriyama; Hiroshi Kataoka; Toshiaki Taoka; Yasuyo Tonomura; Mari Terashima; Masami Morikawa; Emi Tanizawa; Makoto Kawahara; Yoshiko Furiya; Kazuma Sugie; Kimihiko Kichikawa; Satoshi Ueno
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

6.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

7.  Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

Authors:  Mirja Wallner-Blazek; Alex Rovira; Massimo Fillipp; Mara A Rocca; David H Miller; Klaus Schmierer; Jette Frederiksen; Achim Gass; Hugo Gama; Charles P Tilbery; Antonio J Rocha; José Flores; Frederik Barkhof; Alexandra Seewann; Jacqueline Palace; Tarek Yousry; Xavier Montalban; Christian Enzinger; Franz Fazekas
Journal:  J Neurol       Date:  2013-04-26       Impact factor: 4.849

8.  Assessment of biocorrelates for brain involvement in female patients with rheumatoid arthritis.

Authors:  Sherifa A Hamed; Zahra I Selim; Amal M Elattar; Yasser M Elserogy; Eman A Ahmed; Hanan O Mohamed
Journal:  Clin Rheumatol       Date:  2011-06-22       Impact factor: 2.980

Review 9.  Tumefactive demyelination: an approach to diagnosis and management.

Authors:  Todd A Hardy; Jeremy Chataway
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-01-19       Impact factor: 10.154

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  2 in total

1.  Multifocal Tumefactive Demyelination Mimicking Intracranial Neoplasm.

Authors:  Tom George; Soumya Cicilet; Ravi Hoisala; Prithilata Rout
Journal:  J Clin Diagn Res       Date:  2016-03-01

2.  Progression of tumefactive demyelinating lesion in a child demonstrated with MRI.

Authors:  Marta De Simone; Barbara Brogna; Daniele Litterio Spitaleri; Giulio Cicarelli; Roberta Fantozzi; Bruno Guida
Journal:  Radiol Case Rep       Date:  2017-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.